New clinical data being presented at the ASCO from our ongoing KT-253 Phase 1 oncology trial – Kymera Therapeutics
Pearl Freier, Founder of Cambridge BioPartners, shared a post by Kymera Therapeutics on X/Twitter:
” ‘I am pleased to see responses in both liquid and solid tumor patients being treated with KT-253 at doses that do not cause neutropenia or diarrhea,’ said Naval Daver MD, of MD Anderson Cancer Center, and clinical investigator of the KT-253 Phase 1 study. ASCO24, KYMR ‘The responses in post-MPN AML are especially encouraging, as these patients are often refractory to multiple different therapies& therefore represent a subset of AML with high unmet medical need.’ “
Quoting Kymera Therapeutics’s post:
“Today we shared new clinical data being presented at the ASCO Annual Meeting from our ongoing KT-253 Phase 1 oncology trial. KT-253 is a highly potent and selective degrader that targets MDM2, and the findings shared today continue to support our therapeutic hypothesis for MDM2 degradation and the potential to improve the therapeutic index compared to small molecule inhibitors for a variety of cancers. Read the full press release and view the poster here.”
Video attached to the post.
Source: Pearl Freier/X and Kymera Therapeutics/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023